Glioblastoma Multiforme Treatment Market Trends Analysis
Glioblastoma Multiforme are rare tumors with a global incidence of less than 10 per 100,000 people. As per the Delveinsight analysis, the total Glioblastoma multiforme incident population in the 7MM (i.e. the United States, EU5 (the United Kingdom, Germany, Italy, Spain, and France) and Japan) was estimated to be around 2900 in 2017, which is expected to further increase during the forecast period 2017-2030.
To address Unmet needs in the Glioblastoma Multiforme treatment market, several pharmaceutical companies such as Bristol-Myers Squibb, DelMar Pharmaceuticals, AbbVie, Aivita Biomedical, Diffusion Pharmaceuticals, MedImmune, DNAtrix, Apogenix, Kazia Therapeutics, Medicenna Therapeutics, and many others are running clinical trials, investigating their candidates in different stages of clinical development.
To read more on Glioblastoma Multiforme Treatment Market, visit:
https://www.delveinsight.com/blog/glioblastoma-multiforme-treatment-market/